Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04445064
Other study ID # HN1901
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date August 14, 2020
Est. completion date June 8, 2024

Study information

Verified date May 2022
Source Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Contact Jean-Pascal Machiels
Phone +3227645457
Email jean-pascal.machiels@uclouvain.be
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck.


Description:

Patients with a head and neck squamous cell carcinoma eligible for curative treatment are eligible for this proof of concept study. The included patients in arm A will receive IO102 subcutaneous at 100μg every week during the three weeks following the first endoscopy. The included patients in am B (control group) won't receive any treatment. The included patients in arm C will receive IO103 subcutaneous at 100μg every week during the three weeks following the first endoscopy. The main objectives of this study are: - To evaluate the T-cell peptide-specific response to the vaccine in a interferon(INF)-γ ELISpot assay. - To assess the safety and tolerability of the vaccine. - To investigate the decreased action of the IDO enzyme in evaluating the increased tumoral infiltration by CD8+ T-lymphocytes and by measuring the serum levels of kynurenin, tryptophan,... - To evaluate the anti-tumor effect (objective response rate, overall survival, disease free- survival, disease specific survival). - To evaluate the pre-operative activity of peptide vaccine using MRI (Magnetic Resonance Imaging), DWI-MRI (Diffusion Weighted Imaging-MRI) and MRS (Magnetic Resonance Spectroscopy) to visualize possible significant tumor modifications.


Recruitment information / eligibility

Status Recruiting
Enrollment 17
Est. completion date June 8, 2024
Est. primary completion date June 8, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Men and women = 18 years of age on day of signing informed consent. 2. Histologically proven squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx. 3. Patients selected for a surgical treatment. 4. No distant metastases. 5. Measurable disease as per RECIST 1.1. 6. No active second malignancy during the last 3 years except non melanomatous skin cancer or carcinoma in situ of the cervix. 7. The participant provides written signed informed consent for the trial in accordance with ICH-GCP and local legislation prior to admission to the trial. 8. Eastern Cooperative Oncology Group (ECOG) performance status scale 0-1 and Karnofsky score > or = 70. 9. Neutrophil count > 1,500/mm3, platelet count > 75,000/mm3, WBC> or = 3.0/109 L, bilirubin or creatinine < 2 times ULN, ALT or AST < 5 times ULN, Hemoglobin = 9 g/dL. 10. A male participant able to father a child must agree to use contraception starting with the screening visit and throughout the duration of the trial. 11. A female participant is eligible to participate if she is not pregnant not breastfeeding, and at least one of the following conditions applies: 1. Not a woman of childbearing potential (WOCBP). 2. A WOCBP who agrees to follow contraceptive guidance starting with the screening and throughout the duration of the trial. WOCBP are allowed in the trial if they are using proper contraception (follow guidelines from the European Union Heads of Medicines Agency (CTFG, 2014). Exclusion Criteria: 1. Nasopharynx cancer, unknown primary and nasal cavity and paranasal sinuses carcinomas. 2. Previous exposure to immunotherapy. 3. Known diagnosis of immune deficiency or a positive serology of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies). 4. Active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected) or pre-existing liver cirrhosis. 5. Other uncontrolled active illnesses or nonmalignant systemic disease (examples include, but are not limited to, active infections requiring antibiotics, bleeding disorders, uncontrolled diabetes, uncontrolled ventricular arrhythmia, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome). 6. Has received a live vaccine within 30 days prior to the first dose of trial treatment 7. Has an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed. 8. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of trial treatment. 9. Any psychiatric, psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule. 10. Any malignancy (other than squamous cell carcinoma of the head and neck, non-melanoma skin cancer or localized cervical cancer or localized and presumed cured prostatic cancer or basal cell carcinoma of the skin and carcinoma in situ of the cervix or bladder) within the last 3 years prior to registration. 11. Women of Child Bearing Potential (WOCBP) who has a positive urine pregnancy test (e.g., within 72 hours) prior to treatment. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. 12. Pregnant woman and women who are expecting to conceive. 13. Breastfeeding women. 14. Patients expected to father children within the projected duration of the trial.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
IO102
100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)
IO103
100µg each week during the 3 weeks prior to curative treatment (total of 3 to 4 doses maximum)

Locations

Country Name City State
Belgium Cliniques Universitaires Saint-Luc Brussels

Sponsors (1)

Lead Sponsor Collaborator
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Country where clinical trial is conducted

Belgium, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of participants with a T-cell peptide-specific response to the vaccine as assessed by an interferon(INF)-? ELISpot assay. ELISpot responses will be considered positive when the numbers of IFN-? secreting cells will be at least twofold greater than the mean value of the baseline and with a minimum of 50 spots (per 5 × 10^5 peripheral blood mononuclear cell (PBMC) ) detected. 2 years
Secondary Number of participants experiencing toxicity Maximum grade of each toxicity and percentage of patients experiencing toxicity as assessed by CTC-NCIv5.0.
Patients will have blood tests before the second and third administration of the vaccine and 4 weeks after surgery and clinical examinations before each administration of the vaccine and during the 3 months after surgery.
2 years
Secondary Increase in CD8+ T-cell density (cells/mm2) between tumour biopsies taken before and after treatment, as demonstrated by immunohistochemistry. 2 years
Secondary Overall survival (OS) The length of time (in months) from the end of standard treatments during which patients are still alive. 2 years
Secondary Objective response rate (ORR) by RECIST Version 1.1 2 years
Secondary Disease-free survival (DFS) The time (in months) from the end of the surgery to the time of first recurrence, death from any cause or last contact date, whichever occurred first 2 years
Secondary Disease-specific survival (DSS) The time of survival (in months) of patients from the end of treatment to the date of death from a head and neck squamous cell carcinoma, or to the last follow-up date for patients still alive 2 years
See also
  Status Clinical Trial Phase
Completed NCT03650699 - Biofeedback Rehabilitation to Improve Speaking and Eating in Public N/A
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Terminated NCT03053960 - Helical CT, PET/CT, MRI, and CBCT Alone or in Combination in Predicting Jaw Invasion in Patients With Oral Cancer
Recruiting NCT05876247 - Articulatory Adaptation Following Oral Cancer Treatment
Completed NCT03618654 - Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma Early Phase 1
Recruiting NCT04801472 - Optimisation of Potential Dental Implant Sites Protection for Rehabilitation in Patients With Head and Neck Cancer: Impact of Virtual Implants Visualisation on Dosimetry (OPPIDOM) N/A
Recruiting NCT04858269 - First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Phase 2
Active, not recruiting NCT03529604 - Salivary Ap4A, SCCA, TROP2 in Oral Cancer Patients
Completed NCT03028766 - WEE1 Inhibitor With Cisplatin and Radiotherapy: A Trial in Head and Neck Cancer Phase 1
Recruiting NCT05681039 - Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). Phase 2
Completed NCT03510390 - Metformin in Head and Neck Squamous Cell Carcinoma: Effect on Tissue Oxygenation N/A
Recruiting NCT05578170 - Efficacy and Safety of Neoadjuvant Pembrolizumab in III-IVA Resectable Oral Squamous Cell Carcinoma
Recruiting NCT05950737 - Sentinel Node Biopsy in Early Oral Cancers a Tertiary Cancer Centre Experience N/A
Recruiting NCT04333537 - Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer Phase 2/Phase 3
Recruiting NCT03727594 - Radioguided Selective Neck Dissection for Staging and Treatment of Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
Terminated NCT02582008 - Bupropion Hydrochloride or Patient's Choice for Smoking Cessation in Patients With Squamous Cell Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy Early Phase 1
Recruiting NCT05749042 - A Study of Concurrent Chemoradiotherapy Based of Cisplatin With or Without Sintilimab as First-line Therapy for Patients With Advanced Oral Cavity Squamous Cell Carcinoma Phase 2
Recruiting NCT06097468 - Nisin in Oral Cavity Squamous Cell Carcinoma (OCSCC) Phase 1/Phase 2
Withdrawn NCT04892875 - A Study of Concurrent Chemoradiation in Combination With or Without PD1 Inhibitor AB122 Adenosine 2a Receptor / Adenosine 2b Receptor Inhibitor AB928 Therapies in Locally Advanced Head and Neck Cancers Phase 1
Active, not recruiting NCT03784066 - Durvalumab With or Without Tremelimumab in Resectable Locally Advanced Squamous Cell Carcinoma of the Oral Cavity Phase 1/Phase 2